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Acinetobacter species have emerged as major hospital-associated 
pathogens, which have evolved into multidrug-resistant (MDR) 
and extensively drug-resistant (XDR) strains during the past 
decade. [1] Acinetobacter spp. have the capacity to acquire resistance 
to antimicrobial agents through genetic factors such as plasmids and 
pathogenicity islands,[2] resulting in resistant strains that are difficult 
to treat.[3] The Infectious Diseases Society of America has therefore 
declared Acinetobacter spp. among the six antimicrobial-resistant 
pathogens responsible for high morbidity and mortality.[3,4]
Although Acinetobacter spp. are common colonisers that may 
lead to community-acquired infection, they are also opportunistic 
pathogens often found in immunocompromised patients with 
prolonged hospitalisation.[5] Immunosuppressive therapy places 
cancer patients at risk of developing Acinetobacter infections that 
may result in sepsis, respiratory infections, wound infections and 
urinary tract infections.[3,6-8]
XDR Acinetobacter spp. are defined as being resistant to all the tested 
antimicrobials except colistin, whereas pandrug-resistant (PDR) 
isolates are resistant to all agents.[9] A rise in infections from XDR 
Acinetobacter spp. has been reported.[10,11] The global rise of MDR 
Acinetobacter spp. and the emergence of XDR Acinetobacter spp. 
therefore pose a major challenge to current treatment options and 
infection control.[12,13]
Until recently, amikacin was the most active aminoglycoside in 
the treatment of infections caused by Acinetobacter spp. in academic 
complex hospitals in KwaZulu-Natal Province, South Africa (SA). 
It remains the drug of choice for treatment of MDR Acinetobacter 
infections, yet resistance has increased in recent years.[14]
Acinetobacter spp. have several mechanisms of aminoglycoside 
resistance.[15,16] In general, the major mechanism in Gram-negative 
bacteria is enzymatic modification of the amino or hydrolol groups of 
the agent through aminoglycoside-modifying enzymes.
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Background. Drug-resistant Acinetobacter species present serious therapeutic and infection control policy challenges globally. Although 
aminoglycosides have played a crucial role in the treatment of infections with multidrug-resistant (MDR) Acinetobacter spp., recent reports 
indicate that these bacteria are developing resistance to aminoglycosides around the globe.
Objectives. To determine the association between amikacin resistance and clinical outcomes of patients. The minimum inhibitory 
concentrations (MICs) of amikacin against Acinetobacter spp. and genes associated with resistance were also investigated.
Methods. Clinical information from 107 patients with Acinetobacter spp. cultured from clinical specimens was recorded during ward rounds 
at an academic complex hospital in KwaZulu-Natal Province, South Africa, including clinical outcomes, history of antibiotics prescribed 
and microbiological investigations. The 107 Acinetobacter isolates were investigated for susceptibility to antimicrobial agents in use at local 
hospitals. Genes related to amikacin resistance (aphA6 and aacA4) were investigated by polymerase chain reaction (PCR) and sequencing. 
Analysis was performed on the relationship between clinical outcomes and antimicrobial resistance patterns, as well as on the amikacin 
MICs in resistant isolates (n=6) v. their PCR results.
Results. The majority (5/6, 83.3%) of patients with amikacin-resistant Acinetobacter infection were discharged, and 1/6 (16.7%) died. No 
underlying clinical factors were significantly associated with clinical outcome. Amikacin resistance was observed in 6/107 isolates (5.6%), 
with MICs of 32 µg/mL (n=3) and ≥64 µg/mL (n=3) for the amikacin-resistant isolates. All 6 of these isolates were also extensively drug-
resistant (XDR). The aphA6 gene (797 base pair) was detected in all amikacin-resistant isolates.
Conclusions. Most tested Acinetobacter isolates were susceptible to amikacin, underscoring the crucial role of this antibiotic in the 
treatment of MDR Acinetobacter spp. in our hospital. The emergence of XDR isolates is of serious concern and necessitates close monitoring 
and surveillance.
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Amikacin is commonly used at Inkosi Albert Luthuli Central Hospital 
(IALCH), an academic complex hospital in Durban, KwaZulu-Natal, 
owing to the increasing prevalence of MDR Acinetobacter spp., 
especially for nebulisation of pneumonia and in combination with 
piperacillin-tazobactam for systemic infections.
Objectives
To characterise Acinetobacter spp. isolates and compare the clinical 
outcomes of infected patients with the phenotypic and genotypic 
characteristics of XDR Acinetobacter spp. at IALCH.
Methods
The study received ethical approval from the Biomedical Research 
Ethics Committee (BREC), College of Health Sciences, University of 
KwaZulu-Natal (ref. no. BE 283/12).
Study design
The study was analytical and observational experimental research 
that highlighted the prevalence of amikacin-resistant Acinetobacter 
spp., clinical outcomes, and association with genes aphA6 and aacA4, 
related to amikacin resistance.
Patients and bacterial isolates
Clinical information on 107 patients with Acinetobacter spp. 
cultured from clinical specimens was recorded during clinical ward 
rounds at IALCH. The information included clinical outcomes, 
history of antibiotics prescribed at local hospitals as part of routine 
management, and antimicrobial susceptibility patterns of the 107 
Acinetobacter isolates.
The minimum inhibitory concentrations (MICs) for 60 of the 
107 Acinetobacter isolates were investigated. Six amikacin-resistant 
clinical isolates of Acinetobacter spp. were selected for genotypic 
characterisation at the Microbiology Laboratory, National Health 
Laboratory Service, Durban.
Susceptibility testing
Susceptibility testing was performed using the VITEK 2 automated 
system (BioMérieux, France) with the VITEK 2 GN ID card and the 
VITEK 2 AST-N255 card. The MICs of the appropriate antimicrobial 
agents in use were determined for 60 Acinetobacter isolates using 
the Epsilometer test (E-test) (BioMérieux, France). The MIC90 and 
MIC50 were determined for each antibiotic agent tested against 
the 60 isolates. The antibiotics included amikacin, carbapenems 
(imipenem, meropenem), ceftazidime, ciprofloxacin, colistin and 
piperacillin-tazobactam. Acinetobacter ATCC 19606 was used as the 
quality control strain. The results were interpreted according to the 
Clinical and Laboratory Standards Institute.[17] An MIC >32 μg/mL 
for amikacin was considered to indicate resistance.[17]
Polymerase chain reaction and sequencing
Genomic DNA from each of 13 isolates, comprising 6 clinically 
amikacin-resistant strains, 3 controls and 4 known sensitive clinical 
isolates, was extracted using a previously described method.[18]
The presence of the genes related to amikacin resistance (aphA6 
and aacA4) was further investigated by polymerase chain reaction 
(PCR). The MICs of amikacin (n=6) were compared with the PCR 
results of these resistant isolates and clinical outcome.
Clinical and laboratory data collection
Clinical and laboratory data on 107 patients are reported here. The 
data included demographics, underlying medical condition, type of 
specimen, exposure to antimicrobial agents before and after isolation 
of Acinetobacter spp., admission to intensive care units (ICUs) or 
other units, and clinical outcomes. The clinicians defined the type 
of infection. Patients who did not receive specific treatment for 
Acinetobacter spp. were classified as colonised. Clinical response to 
treatment was classified as successful in patients whose infection-
defining signs and symptoms resolved and as failed for patients who 
deteriorated or whose signs and symptoms persisted.
Statistical analysis of the data
The data were captured, standardised and analysed using the 
Statistical Package for Social Sciences (SPSS), version 19 (IBM, USA). 
The association between underlying conditions and outcome was 
analysed using Pearson’s χ2 test. Logistic regression analysis was used 
to test for factors associated with survival status of patients.
Results
Susceptibility of Acinetobacter spp. isolates (N=107)
Six isolates (5.6%) that were resistant to amikacin were defined as 
XDR based on their antibiograms. Eighty isolates (80/107, 74.8%) 
were MDR. The rest were resistant to fewer than three different classes 
of tested agents and were therefore not classified as MDR (Table 1). 
Table 2 shows the antimicrobial MICs of 60 Acinetobacter isolates.
Table 1. Drug resistance patterns of Acinetobacter spp. 
isolates from clinical specimens (N=107)
Antibiotic susceptibility n (%)
MDR Acinetobacter spp. 80 (74.8)
XDR Acinetobacter spp.* 6 (5.6)
PDR Acinetobacter spp. 0
Amikacin resistant* 6 (5.6)
Resistant to <3 tested agents (not MDR) 15 (14.0)
Total 107
MDR = multidrug resistant; XDR = extensively drug resistant; PDR = pandrug resistant.
*Same Acinetobacter spp.
Table 2. MIC50 and MIC90 of the Acinetobacter spp. isolates from clinical specimens (N=60)
Antibiotics MIC50, (µg/mL) MIC90, (µg/mL)
MICs (CLSI) (µg/mL)
Sensitive Resistant 
CST 0.25 0.5 <0.5 >0.5 
IMP 24 >32 <1 >4
MEM 24 >32 <1 >4
TZP >256 >256 16 >32
AK 8 16 16 >64
CIP >32 >32 0.5 4
CAZ >16 >16 16 >16
MIC = minimum inhibitory concentration; CLSI = Clinical and Laboratory Standards Institute; CST = colistin; IMP = imipenem; MEM = meropenem; TZP = piperacillin-tazobactam;  
AK = amikacin; CIP = ciprofloxacin; CAZ = ceftazidime.
51       January 2020, Vol. 110, No. 1
RESEARCH
Among the 6 amikacin-resistant isolates, the 
MICs of amikacin ranged between 32 and 
≥64 µg/mL (Table 2).
Detection of aphA6 and aacA4 genes
Six cases with amikacin-resistant Acineto-
bacter spp. were identified. The clinical 
characteristics and outcome of those 
6  patients and MICs of tested antibiotics 
(n=6) are shown in Table 3.
PCR amplification allowed for detection 
of the aphA6 gene (797 base pair (bp)) from 
the 6 amikacin-resistant Acinetobacter spp. 
clinical isolates (Fig. 1). However, the aacA4 
gene (489 bp) was not present in these 
isolates (Fig. 2.).
Phenotypic and genotypic 
analysis of the amikacin-resistant 
Acinetobacter spp.: Correlation  
of antibiogram with aphA6 and  
aacA4 genes
The MICs of amikacin and other tested 
drugs are shown in Table 2. The 6 amikacin-
resistant strains were sensitive only to 
colistin and therefore defined as XDR 
Acinetobacter spp. (Table 3). These 6 strains 
were phenotypically resistant and showed 
the presence of the aphA6 gene but not the 
aacA4 gene (Figs 1 and 2).
Demographic features, clinical 
characteristics and outcomes of 
all patients with infections due to 
Acinetobacter spp. (N=107)
Clinical data were analysed using simple 
descriptive analysis. The demographic data 
on patients with Acinetobacter infection 
(N=107) are shown in Table 4. Acinetobacter 
spp. were most commonly isolated from 
adult patients in non-ICU wards and in 
neonates or paediatric patients.
Underlying diseases
Acinetobacter spp. were cultured most 
commonly in adults presenting with trauma 
and injury, and in paediatric patients with 
congenitally abnormal organs. Trauma was 
predominant overall. Retroviral disease, 
cancer and other conditions showed little risk 
of colonisation and infection (Table  4). No 
statistically significant differences (p>0.05 
(0.151)) were observed between children and 
adults with medical and surgical conditions 
with regard to the presence of Acinetobacter 
infections.
Table 3. Patients’ clinical characteristics and outcome, and MICs of other antimicrobial agents tested against amikacin-resistant 
Acinetobacter spp. (N=6)
Isolates
MIC (µg/mL)
Ward Specimen
Days in 
hospital Treated with OutcomeIMP MEM AK TZP CAZ CIP CST
AK-R >16 >16 >64 >128 64 >4 <0.5 LW BC 15 TZP + AK/MEM + 
CST
Discharged
AK-R >16 >16 >64 >128 64 >4 <0.5 ICU Pus 23 TZP + AK Died
AK-R >16 >16 >64 >128 64 >4 <0.5 ICU ETA 28 CST Discharged
AK-R >16 >16 32 >128 64 >4 <0.5 HCU BC 35 CST Discharged
AK-R 8 >16 32 >128 64 >4 1 PU Pus 43 None Discharged
AK-R >16 >16 32 >128 64 >4 0.5 VU Pus 29 None Discharged
MIC = minimum inhibitory concentration; AK-R = amikacin resistant; IMP = imepenem; MEM = meropenem; AK = amikacin; TZP = piperacillin-tazobactam; CAZ = ceftazidime;  
CIP = ciprofloxacin; CST = colistin; LW = labour ward; ICU = intensive care unit; HCU = high-care unit; PU = plastic unit; VU = vascular unit; BC = blood culture; ETA = endotracheal aspirate; 
None = no antibiotics given.
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Fig. 1. Polymerase chain reaction for detection of the amikacin-resistant aphA6 gene of Acinetobacter 
spp. Lanes 1 - 4 and 7 - 8: amikacin-resistant strains (9, 11, 15, 31, 42, 51) (aphA6 gene detected); 
lanes 5, 6, 9, 10: amikacin-sensitive strains (8, 20, 25, 60) (aphA6 gene bands absent); lane 11: negative 
control; lane 12: positive control; lane 13: MWM. (MWM = molecular weight marker; bp = base pair.)
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Fig. 2. Polymerase chain reaction for detection of the amikacin-resistant aacA4 gene of Acinetobacter 
spp. Gene absent in all tested isolates. Lanes 1 - 11: isolates; lane 12: positive control; lane 13: MWM. 
(MWM = molecular weight marker; bp = base pair.)
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Antibiotic use
Tazocin (piperacillin-tazobactam), ciprofloxacin and meropenem 
were used in most cases. Colistin monotherapy and colistin 
combinations were not commonly used. Analysis revealed that 
infections with Acinetobacter spp. were treated mostly with a 
piperacillin-tazobactam and amikacin combination, while for XDR 
strains colistin monotherapy or other combinations were used 
according to the specific characteristics of individual cases (Table 4). 
Use of colistin, combinations and amikacin differed significantly 
between adult and paediatric patients (p<0.05 (0.018)).
Clinical outcome
The majority of the patients (67/107, 62.6%) were discharged, but 
mortality was high at 21.5% (n=23) (Table 4). Clinical outcome was 
not significantly associated with age (p>0.05 (0.942)).
Clinical characteristics and outcomes of patients infected 
with amikacin-resistant Acinetobacter spp. (n=6)
All 6 patients with amikacin-resistant Acinetobacter infections were 
hospitalised in different units for >2 weeks (21 - 43 days) with chronic 
illness (Table 3). Two isolates were obtained from blood culture, 3 
from pus swabs and 1 from an endotracheal aspirate. Two patients 
with significant Acinetobacter infections were treated with colistin, 
while 2 with colonisation received no antibiotics. One of the 6 died, 
and 5 recovered and were discharged (Table 4).
Discussion
Despite Acinetobacter spp. being classified by the Infectious Diseases 
Society of America a decade ago as one of the six most important 
MDR micro-organisms in hospitals worldwide,[3,4,19] drug-resistant 
Acinetobacter spp. still present a serious therapeutic and infection 
control challenge. Increasing antimicrobial resistance among 
Acinetobacter, resulting in the evolution of XDR and PDR strains, 
has been documented globally.[12]
The present study revealed the presence of amikacin-resistant 
Acinetobacter spp. at IALCH, with 6 (5.6%) of 107 isolates being 
amikacin resistant and sensitive only to colistin, defined as XDR 
Acinetobacter spp.
In our setting, amikacin is commonly used with piperacillin-
tazobactam as a second-line treatment option and amikacin 
nebulisation for pneumonia cases as general antibiotic policy. 
Fortunately, 101 (94.4%) of 107 Acinetobacter spp. isolates were 
Table 4. Demographic and clinical data on patients with Acinetobacter spp. cultured from clinical specimens (N=107)
<1 year (N=20), n Paediatric >1 year (N=8), n Adult (N=79), n p-value
Sex 
Male 12 6 46
Female 5 1 31
NA 3 1 2
Ward
ICU, paediatric 5 1  -
Paediatric surgery 1 1  -
Neonatal 14 -  -
Paediatric oncology - 2  -
Paediatric medical unit - 1  -
Trauma - 2 -
NA - 1  6
ICU, adult - - 18
Non-ICU - - 55
Underlying disease 0.151 (>0.05)
RVD 5 - 7
Abnormal organ (congenital ) 10 -  -
Respiratory disease 2 1  -
Sepsis 3 -  -
Cancer - 2 3
Surgical - 17
Medical - 2 20
Injury/trauma - 3 32
Antibiotic history 0.018 (<0.05)
CZT 1 11
CZT + combination - 1
AK (nebulisation) 1 2 11
Others (TZP, CIP, MEM) 17 4 30
No antibiotics given 1 2 26
Outcome 0.942 (>0.05)
Discharged (67/107, 62.6%) 10 8 49
Died (23/107, 21.5%) 6 - 17
NA (17/107, 15.9%) 4 - 13
NA = not available; ICU = intensive care unit; RVD = retroviral disease; CZT = colistin; AK = amikacin; TZP = piperacillin-tazobactam; CIP = ciprofloxacin; MEM = meropenem.
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highly sensitive to amikacin. In the past, aminoglycosides have 
played a crucial role in the treatment of infections with MDR 
Acinetobacter spp. However, Lee et al.[20] reported that Acinetobacter 
were developing resistance to aminoglycosides around the globe. 
The current study showed that amikacin-resistant Acinetobacter 
isolates at IALCH carried the aphA6 gene but not the aacA4 gene. 
At 5.6%, the prevalence was significantly lower in our local setting 
than in Korea, according to the 2009 Korean Nationwide Surveillance 
on Antimicrobial Resistance (KONSAR) study, where amikacin-
resistant Acinetobacter spp. increased to 48%.[20]
Our data analysis identified a potential emerging challenge to 
treatment and clinical management that was elucidated by phenotypic 
and genotypic characterisation of Acinetobacter spp. The study 
highlights the crucial role of standard amikacin use, as can be seen 
by the MIC50 and MIC90 of amikacin within the sensitive range, while 
the MIC50 and MIC90 of imipenem, ciprofloxacin, ceftazidime and 
piperacillin-tazobactam in the tested isolates were within the highly 
resistant range (Table 2).
Treatment of MDR Acinetobacter spp. infection usually requires 
the use of appropriate drugs such as piperacillin-tazobactam 
plus amikacin, ciprofloxacin, ceftazidime, carbapenem, colistin 
and tigecycline based on the local antibiogram or individualised 
microbiological results. Infections with Acinetobacter spp. were mostly 
treated with piperacillin-tazobactam plus amikacin, whereas colistin 
monotherapy or combinations were used for XDR Acinetobacter spp. 
according to the individual case.
Previous studies[1,21,22] have reported MDR Acinetobacter-associated 
sepsis to be most common in ICU patients. The present study showed 
that Acinetobacter infections were common in both non-ICU and 
ICU wards. Infections in the ICU were mainly associated with trauma 
cases. All isolates were cultured from the specimens after 21 - 43 days 
of hospitalisation and prior to amikacin exposure.
Infection with Acinetobacter spp. was most prevalent in patients 
aged 25 - 60 years, and in non-ICU, trauma and postoperative 
paediatric units. Trauma cases were predominant overall, because 
Acinetobacter spp. are part of the skin flora and an environmentally 
acquired organism. Moreover, in the present study, patients in the 
academic hospital with retroviral disease, cancer and other clinical 
conditions were not prone to colonisation and infection, possibly 
because of strict infection prevention and control measures in all 
high-care units.
The majority of the 107 patients were treated with antibiotics such 
as piperacillin-tazobactam, amikacin, ciprofloxacin and meropenem 
according to the local protocol. However, colistin monotherapy, 
drug combinations and the combination of amikacin with tazocin 
were used significantly more often in adult patients than paediatric 
patients (p<0.05 (0.018)). Infection with XDR Acinetobacter spp. 
was treated with colistin monotherapy or combinations according 
to the individual case based on consultation between the clinician 
and the microbiologist. Our study highlighted that colistin is a 
key therapeutic option for the treatment of infections with XDR 
Acinetobacter spp. This finding also indicates the need to enhance 
infection prevention and control measures and antibiotic stewardship 
programmes.
As far as we are aware, this study is the first to describe detailed 
clinical and molecular characteristics of amikacin-resistant 
Acinetobacter spp. at IALCH, a public academic hospital in KwaZulu-
Natal. Molecular analysis suggested a potential mechanism of 
amikacin resistance to be the presence of the aphA6 gene.
Underlying clinical diseases were not significantly associated with 
clinical outcome in patients with Acinetobacter spp. infections.
A surveillance report for 2016 from the SA private sector[23] showed 
that 47% and 37% of A. baumannii isolates were non-susceptible 
to the aminoglycosides gentamicin and amikacin, respectively. 
Although the proportion resistant to amikacin has increased in 
private hospitals, the above study did not include molecular analysis. 
Molecular epidemiological studies are required when investigating 
transmission dynamics, which will in turn inform intervention 
strategies to prevent the spread of drug-resistant strains. Infection 
prevention and control should also aim to identify reservoirs and 
sources of infection to recognise and prevent further spread of MDR, 
XDR and PDR Acinetobacter spp.
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